In the dawn 🌞 of July 2025, as summer sun lit greenhouses and hemp fields alike 🌱, the cannabis and hemp industries entered a quarter of profound shifts. We follow a cast of regulatory actors, corporate players, and legislatures—each weaving into a larger tapestry of change 📝.

By the end of Q3, the Global Cannabis Stock Index 🤑 had rallied approximately 53 % in that quarter alone 🚶🏻‍♀️, pushing its year-to-date gains into positive territory—despite earlier volatility.The rebound was spearheaded 📍 by standout performers like Tilray, which soared 317.5 % over the period, and Organigram and GrowGeneration, which also posted double-digit growth 💰. New Cannabis Ventures

This revival 🧌 of investor appetite speaks to renewed confidence in growth trajectories, valuation resets, and perhaps a recalibration of risk appetite in the sector. The lesson 👊🏼? In cannabis equities, sentiment and policy shifts are just as potent as fundamentals.

Q3 witnessed sharp clashes on Capitol Hill 🗽. A House subcommittee advanced a bill that would bar the Department of Justice from rescheduling cannabis, directly opposing the Biden administration’s push toward reclassification. Meanwhile, both the House and Senate appropriations committees moved to redefine “hemp 🐸” and ban many hemp-derived THC products such as delta-8️⃣ and THCA—an aggressive shift with far-reaching consequences for multi-state operators. Concurrently, the DEA’s 👮🏽‍♂️ rescheduling appeal process has languished for over half a year, hampered by leadership turnover and administrative inertia. JD Supra. The net 🕸 effect: regulatory whiplash and deep uncertainty for firms mapping compliance strategies.

In mid-2025, Texas Governor Greg Abbott vetoed a sweeping bill (Senate Bill 3) that sought to ban all THC products, including delta-8 THC—something the state had previously legalized under the 2018 Farm 🚜 Bill. The veto preserved the multibillion-dollar hemp/THC ecosystem and safeguarded 🔴 tens of thousands of jobs tied to production, distribution, and retail. Axios

This decision underscored how political risk remains a double-edged sword 🗡️: bold reforms can swing either way—and in this case, the preservation of industry status quo was relatively rare in 2025.

On October 🎃 1, 2025, the FDA formally added cannabis products to its adverse event reporting form, expanding pharmacovigilance efforts to include cannabis derivatives and hemp-based items. Marijuana Moment This integration reflects 🪞 growing regulatory willingness to treat cannabis with a degree of medical-style rigor, and suggests that oversight may intensify around safety, side effects, and post-market surveillance 🚨.

In Q3, Maryland reported roughly US $18.4 million 💶 in cannabis tax revenues, following an excise tax increase from 9 % to 12 % on July 1. The additional 3 % portion was diverted toward a new General Fund, with earmarks 👂 for public health, community reinvestment, and municipal allocations. CBS News

This inflow affirmed that tax policy 🎗️ remains a central lever in state cannabis economics—and provides a quantitative benchmark for other states watching revenue outcomes.

Public operators 👩‍💻 offered evolving guidance in Q3. Tilray reported net revenue of US $185.8 million, slightly down year-over-year but emphasizing margin control and cost discipline. Tilray Meanwhile, High Tide Inc. (Canadian 🇨🇦 retail operator) projected record revenue and adjusted EBITDA, with same-store sales up 7.4 %—its strongest in two years. High Tide Inc.

Analysts flagged 🚩 that these positive signals may reflect inventory resets and seasonal upticks—yet the sector must still prove consistent profitability to justify lofty multiples.

Legislative efforts in multiple jurisdictions sought to redraw ✏️ the boundary between hemp and cannabis. At the federal level, attempts to redefine hemp threatened to ban certain THC derivatives formerly allowed under 0.3 % thresholds. JD Supra In Kentucky 🐴, four out of six U.S. House members publicly opposed proposals to ban some hemp products. Courier Journal

Simultaneously, Maryland’s high court declared that many hemp-derived psychoactive 🎅 products were inherently illegal under state law. MJBizDaily These conflicting regimes generate compliance chasms for companies operating across state lines 〽️.

In early October, Kansas state authorities raided ten retail locations across six cities 🏭, targeting shops selling high-THC marijuana and THC products deemed illegal. The Attorney General and KBI framed it as a crackdown on youth 👦🏻 exposure and illicit supply chains. Kansas Reflector

Elsewhere, New York’s Office of Cannabis Management padlocked 207 unlicensed cannabis stores, while licensed sellers gained ground and legal storefront counts rose 🌷. MarketWatch These enforcement bursts remind operators: regulatory tolerance is volatile and local.

2025 marks the centenary of international cannabis prohibition 📮, dating to the 1925 International Opium Convention’s restrictions. Around the world 🏞️, activists and scholars have used the centennial to reexamine decades of research suppression, genetic resource loss, and missed opportunities in hemp and cannabis science. Wikipedia

This symbolic moment invites deeper inquiry: how much has prohibition hindered botanical breeding, crop 🌽 diversification, and commercial uses of fiber, nutrition, and medical derivatives?

The consumer goods realm saw a curious entry: Edible 👄 Brands (parent of Edible Arrangements) launched Edibles.com, a marketplace for hemp-derived edibles, beverages, and gummies 🥭. The launch initially targets Texas, with plans to expand into Southeast states. Food & Wine. This move underscores ⚫ how mainstream CPG infrastructure and branding are creeping into cannabinoid product spaces—blurring lines between consumer snack 🍇 goods and regulated cannabinoids.

As summer matured, investor capital, policy pressure, and regulatory risk formed tension arcs. The equity rally (Story 1) 🃏 was enabled by tentative optimism in policy corridors (Story 2), yet faced counterweights in legislative overreach (Story 7) and enforcement crackdowns (Story 😎 🀄. Texas’s veto (Story 3) served as a steadying hand, preserving business continuity, while FDA’s adverse event move (Story 4) signaled creeping oversight. State tax windfalls (Story 5) provided a fiscal incentive for expansion, even as public operators (Story 6) sought to legitimize their models. The centennial (Story 9) invited introspection into the industry’s roots, and consumer CPG deployment (Story 10) suggested how matured supply chains might absorb cannabinoids 🫧 into mainstream commerce. Each thread forms a mosaic of momentum, friction, and critical inflection.

As Q3 2025 closes, the cannabis and hemp industries stand at a nexus: bullish sentiment ignites expansion, but policy volatility 🌪️ looms large. What if—contrary to mainstream hopes—the regulatory pendulum swings backward instead of forward?

Imagine a scenario 💭: a backlash from conservative blocs, combined with isolated high-profile health incidents linked (rightly or wrongly) to cannabinoid products, triggers a regulatory rollback. In this alternate future:

This reversal scenario may feel extreme 🪂, but it’s grounded in real political risk, enforcement precedent, and diverging legal views teased out in Q3 debates (Stories 2, 7, 8). The lesson: while optimism should be anchored in data, no sector tethered to shifting legal frameworks is invulnerable 🏋️‍♂️.

Do you believe cannabis in 2026 will be defined more by expansionary breakthroughs 💚 or restrictive 🏛️ backlashes?

🐛 EVOLVE 🦋

The information provided in this newsletter is for informational purposes only and does not constitute medical, legal, or professional advice. Always consult with a qualified professional before making any decisions based on the content shared here.